Advicenne (Euronext Growth Paris:ALDVI), a specialty pharmaceutical company focused on rare kidney diseases, announced on Monday that the US Food and Drug Administration (FDA) has accepted for review its New Drug Application for Sibnayal (ADV7103), a fixed combination of potassium citrate and potassium bicarbonate for the treatment of distal Renal Tubular Acidosis (dRTA).
The FDA has set a target action date under the Prescription Drug User Fee Act (PDUFA) of 3 September 2026.
Advicenne submitted the NDA on 2 November 2025, and the FDA completed its standard 60-day filing review, during which the company addressed questions raised by the agency. The 505(b)(2) application incorporates European clinical studies that supported the recently renewed Marketing Authorization dossier in Europe.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval